Navigation Links
Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))
Date:7/14/2009

SAN DIEGO, July 14 /PRNewswire/ -- With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient. In obtaining a result from the VerifyNow System, physicians are provided objective information to determine the response of an individual patient to their antiplatelet therapy, regardless of the P2Y12 inhibitor that is prescribed.

"We are very excited with our product position and timing with the release of this therapeutic alternative to Plavix," said Timothy I. Still, President and CEO of Accumetrics. "We feel the VerifyNow System can dramatically contribute to a physician's ability to enhance care for patients undergoing percutaneous coronary intervention and receiving the antiplatelet therapy that follows. In having this alternative therapy, physicians can now utilize the results of the VerifyNow System to assist in the selection of the therapy that best achieves the desired antiplatelet effect."

Accumetrics' VerifyNow P2Y12 Test is used to measure the level of P2Y12 receptor blockade and has been in used globally to assess a patient's response to both clopidogrel and prasugrel in clinical trials as well as in clinical practice within the hospital and physician office settings.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a registered trademark of Lilly-Daiichi Sankyo.

    CONTACT:
    Jules Abraham
    Lippert/Heilshorn & Associates
    212-838-3777
    jabraham@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com


'/>"/>
SOURCE Accumetrics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Accumetrics, Inc. Announces Distribution Channels in Israel and Cyprus
2. Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial
3. Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited
4. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
5. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
6. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
7. New White Paper from The Beryl Institute Provides Insights to Generations
8. Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide
9. Zix Corporation CEO Provides Corporate Update for Second Quarter 2009
10. King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan
11. New Partnership Between FirstCare and HealthFitness Provides Cost-Effective Preventive Health Solutions for Small- to Mid-Size Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 20, 2016 According to the 2016 ... increasing demand for affordable healthcare solutions as since the early ... rise. In countries like the US, the healthcare cost rose ... the consumer price index inflation rate stood at an average ... up to 3.62% during the same time period. This can ...
(Date:5/19/2016)... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is ... a chance to meet iconic entertainer Mario Kreutzberger ... past two years has been the face of the company,s ... with type 2 diabetes, which Don Francisco is ... and tips for long-term healthy lifestyle choices. ...
(Date:5/19/2016)... , The data will be presented ... 8006)   The conclusions of the study point to ... with 90% of the m presenting duration ... two percent of the patients had clinical benefit.   ... Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients ...
Breaking Medicine Technology: